Publications by authors named "J P Cote"
Background: Telehomecare monitoring (TM) in patients with cancer is a complex intervention. Research shows variations in the benefits and challenges TM brings to equitable access to care, the therapeutic relationship, self-management, and practice transformation. Further investigation into these variations factors will improve implementation processes and produce effective outcomes.
View Article and Find Full Text PDFThe epigenetic cofactor ENL (eleven-nineteen-leukemia) and the acetyltransferase MOZ (monocytic leukemia zinc finger) have vital roles in transcriptional regulation and are implicated in aggressive forms of leukemia. Here, we describe the mechanistic basis for the intertwined association of ENL and MOZ. Genomic analysis shows that ENL and MOZ co-occupy active promoters and that MOZ recruits ENL to its gene targets.
View Article and Find Full Text PDFBackground: Patients who experienced acute kidney injury (AKI) may benefit from dedicated care following hospital discharge. Most of these patients will be followed by primary care providers. There is a lack of data on current practices and comfort for these care providers when offering post-AKI care.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the occurrence and risk factors of adverse events (AEs) related to intravenous immunoglobulin (IVIG) therapy in hospitalized children under 18 years old.
- A total of 228 patients were reviewed, resulting in 478 IVIG treatments, with mild reactions like fever and headache being the most common, although some reactions were severe.
- Key predictors of IVIG-AEs included older age, dehydration, allergies, being on the first treatment, and receiving higher doses, while concurrent steroid use seemed to reduce risk.
Article Synopsis
- - The debate around first line autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has intensified, especially for standard-risk patients, while high-risk patients still face poor treatment outcomes.
- - Current best practices for transplant-eligible MM (TEMM) now include a quadruplet induction therapy that combines an anti-CD38 monoclonal antibody with a proteasome inhibitor and an immunomodulatory drug, followed by maintenance therapy.
- - The Canadian Consensus Guideline Consortium (CGC) is providing recommendations on various aspects of treatment for TEMM, including ASCT eligibility, induction therapy, and management of high-risk patients, with plans to review and update these guidelines regularly.